Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.45 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6048568 | 0.81 | TAAR1 (0.50) | HTR2A | |
| SCHEMBL17345424 | 0.78 | SLC6A4 (0.44) | SLC6A4SLC6A2SLC6A3HTR2AALDH1A1 | |
| SCHEMBL4537 | 0.78 | LIPG (0.50) | SLC6A4SLC6A2SLC6A3HTR2AALDH1A1 | |
| SCHEMBL29504654 | 0.78 | LIPG (0.50) | SLC6A4SLC6A2SLC6A3HTR2AALDH1A1 | |
| SCHEMBL735118 | 0.74 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3HTR2AKCNH2 | |
| SCHEMBL125255 | 0.73 | ALDH1A1 (0.57) | SLC6A4SLC6A2SLC6A3HTR2AALDH1A1 | |
| SCHEMBL29729780 | 0.73 | ALDH1A1 (0.57) | SLC6A4SLC6A2SLC6A3HTR2AALDH1A1 | |
| SCHEMBL20385177 | 0.73 | IDO1 (0.36) | ALDH1A1KCNH2 | |
| SCHEMBL20312337 | 0.69 | MAPT (0.38) | ALDH1A1TSHRLMNA | |
| SCHEMBL27376316 | 0.69 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3HTR2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202953-B1 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-08-30 | — | — | EP | disclosed |
| US-6710080-B2 | ANALGESICS | GRUENENTHAL GMBH (DE) | 2004-03-23 | — | — | US | disclosed |
| US-20020198251-A1 | Substituted 2-dialkylaminoalkylbiphenyl derivatives | GRUENENTHAL GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| EP-1202953-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010816-A2 | SUBSTITUTED 2-DIALKYLAMINOALKYLBIPHENYL DERIVATIVES | Grünenthal GmbH (DE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198251-A1 | Substituted 2-dialkylaminoalkylbiphenyl derivatives | LIPA, PKD1, PKD2 | SLC6A4 1586/4885SLC6A2 1499/4885SLC6A3 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.